Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL

Kerry Rogers, MD
Published: Sunday, Dec 10, 2017


Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Having CLL, whether or not is has been treated, puts people at risk for secondary cancers and a higher rate of infection. As targeted agents become developed, the question becomes whether early intervention with these agents, like ibrutinib, can help patients avoid infectious complications, Rogers explains.
 

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Having CLL, whether or not is has been treated, puts people at risk for secondary cancers and a higher rate of infection. As targeted agents become developed, the question becomes whether early intervention with these agents, like ibrutinib, can help patients avoid infectious complications, Rogers explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x